Skip to main content
. 2019 Feb 21;8(2):190. doi: 10.3390/cells8020190

Table 1.

mTOR inhibitors used alone or in association in T-ALL.

Drug Drug Target Reported Synergism Clinical Trials Reference(s)
Rapamycin
(Sirolimus)		 mTORC1

  • Doxorubicin

  • Janus kinase inhibitor

  • ABL protein inhibitors

  • Focal Adhesion Kinase (FAK) inhibitor

  • Cyclin D3 and CDK4/6 inhibitors

  • Cyclophosphamide

  • Methotrexate

  • γ-secretase inhibitors

  • CCI-779

 NCT00968253
NCT01184885 		[80,82,84,86,87,88,89,90,96,105,106,107]
CCI-779
(Temsirolimus)		 mTORC1 Doxorubicin NCT01614197
NCT01403415 		[80,81,82,96,105,142,182]
RAD001
(Everolimus)		 mTORC1

  • LEE-01

  • Glucocorticoids

 NCT03328104 [80,82,89,91,92,96,97,182]
PKI-587
(Gedatolisib)		 PI3K/mTOR - - [6,83,84]
BEZ235 PI3K/mTOR

  • cytarabine (AraC)

  • Doxorubicin

  • Dexamethasone

 - [6,84,111,112,113,114]
AZD8055 mTORC1/mTORC2 PP-242 - [79,85,115]
OSI-027 mTORC1/mTORC2 - - [79,85,116]